Advanced Filters
noise
Found 842 clinical trials

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)

30 - 74 years of age All Phase 1
R RABOIS Emilie

Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease.

This study will compare smartphone usage data between three groups of patients diagnosed with either a memory complaint, mild cognitive decline, or Alzheimer's disease.

60 years of age All Phase N/A
S Stacey Monsell

Gamma Induction for Alzheimer's Disease

Alzheimer's Disease (AD) is characterized by amyloid-β (Aβ) plaque buildup and phosphorylated tau (p-tau) in the brain, as well as widespread neurodegeneration. Amyloid-β and tau are proteins that build up in the brain that may contribute to memory problems. The evidence suggests that both amyloid and tau play a critical …

45 years of age All Phase 1/2
F For more information at the NIH Clinical Center contact Office of Patient Recruitment (OPR)

PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease

Background About 5 million adults in the U.S. have Alzheimer s disease or another adult-onset neurodegenerative disorder. Many studies have found that inflammation in the brain contributes to these diseases. Researchers want to find a better way to measure this inflammation. Objective To learn whether COX-1 and/or COX-2 is elevated …

18 - 99 years of age All Phase 1
J Jean-Michel DOREY, MD, PHD

Neurofilament Light Chains and Cognitive Impairment in Chronic Psychiatric Disease

The validation of biomarkers allowing the discrimination of cognitive and behavioral disorders of psychiatric origin from those of neurodegenerative origin would facilitate diagnosis and improve patient management. Neurofilaments, which are markers of neuronal lysis, appear to be a promising biomarker. In a previous preliminary study, the investigators demonstrated significantly lower …

45 - 80 years of age All Phase N/A
M Marzena Zboch

A Study of NTRX-07 in Participants With Alzheimer's Disease

Study Overview NeuroTherapia Inc. is conducting a clinical study to explore the safety and effects of a new drug called NTRX- 07. This drug targets people with mild cognitive impairment (MCI) or mild to moderate Alzheimer's disease (AD). The study's primary focus is on safety and how the drug interacts …

65 - 80 years of age All Phase 2
D Dr. Gomez-Morales

Early-Stage Partner in Care Living Alone Plus

EPICLA+ (Early-Stage Partners in Care Living Alone Plus) is a research project designed to assist people with early-stage memory loss who live alone in the community by providing early-stage related education and skill-training sessions, held via Zoom, designed to reduce stress, enhance well-being, manage challenges, and plan for the future. …

60 years of age All Phase N/A
N Nancy Aruscavage

LEADing Dementia End-of-Life Planning Conversations

Advance care planning is important for all adults, but perhaps even more so for the 5.7 million persons with Alzheimer's disease or related dementia (ADRD), due to the progressive and protracted cognitive deterioration associated with the disease process. In the context of ADRD, medical decision-making at the end of life …

18 years of age All Phase N/A
P Paula Desplats

TREAD: Time Restricted Eating Intervention for Alzheimer's Disease

The goal of this clinical trial is to learn if restricting the time of eating to allow for prolonged fasting at night may reduce sleep disturbances, cognitive decay, and pathology in patients diagnosed with Mild Cognitive Impairment (MCI) or early to moderate Alzheimer's disease (AD). It will also learn about …

60 years of age All Phase 1
C Chieh-Hsin Lin, MD, PhD

Novel Augmentation of DAOIB and Antioxidant for Early Dementia

Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property …

50 - 90 years of age All Phase 2

Simplify language using AI